Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPP IV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or ‘gliptins’) have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.
1. Mentlein R.Dipeptidyl-peptidase IV (CD26)- role in the inactivation of regulatory peptides. Regul Pept1999;85:9–24.
2.
2. Gorrell MD, Gysbers V, Mccaughan GWCD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol2001;54:249–64.
3.
3. Green BD, Flatt PR, Bailey CJInhibition of dipeptidyl peptidase IV activity as therapy of diabetes. Expert Opin Emerging Drugs2006;11:525–39.
4.
4. Green BD, Gault VA, O'Harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des2004;10:3651–62.
5.
5. Holst JJ.GLP-1 in NIDDM. Diabet Med1996;13:S156–S160.
6.
6. Holst JJ.Glucagon-like peptide-1: from extract to agent. Diabetologia2006;49:253–60.
7.
7. Green BD, Gault VA, O'Harte FP, Flatt PR. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br J Diabetes Vasc Dis2005;5:134–40.
8.
8. Deacon CF, Ahren B, Holst JJInhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opin Investig Drugs2004;13:1091–102.
9.
9. Drucker DJ.Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs2003;12:87–100.
10.
10. Brubaker PL, Drucker DJMinireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology2004;145:2653–9.
11.
11. Rudovich NN, Rochlitz HJ, Pfeiffer AFReduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. Diabetes2004;53:2359–65.
12.
12. Valverde I, Morales M, Clemente F. et al.Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett1994;349:313–16.
13.
13. O'Harte FP, Gray AM, Abdel-Wahab YH, Flatt PR. Effects of non-glycated and glycated glucagon-like peptide-1 (7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides1997;18:1327–33.
14.
14. Yang H, Egan JM, Wang Y. et al.GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol1998;275:C675–C683.
15.
15. Trapote MA, Clemente F, Galera C. et al.Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver. J Endocrinol Invest1996;19:114–18.
16.
16. McIntosh CH, Bremsak I, Lynn FC. et al.Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin. Endocrinology1999;140:398–404.
17.
17. Miyawaki K, Yamada Y, Ban N. et al.Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med2002;8:738–42.
18.
18. Oben J, Morgan L, Fletcher J, Marks VEffect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1 (7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol1991;130:267–72.
19.
19. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J. Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extra-pancreatic sites of GLP-1 action. Endocrinology1994;135:2070–5.
20.
20. Meier JJ, Gethmann A, Nauck MA. et al.The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab2006;290:E1118–23.
21.
21. Aertgeerts K, Levin I, Shi L. et al.Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem2005;280:19441–4.
22.
22. Gorrell MD.Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci2005;108:277–92.
23.
23. Maes MB, Lambeir AM, Gilany K. et al.Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J2005;386:315–24.
24.
24. Nikolaidis LA, Elahi D, Shen YT, Shannon RPActive metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol2005;289:H2401–08.
25.
25. Marguet D, Baggio L, Kobayashi T. et al.Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA2000;97:6874–9.
26.
26. Nagakura T, Yasuda N, Yamazaki K. et al.Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun2001;284:501–06.
27.
27. Yasuda N, Nagakura T, Yamazaki K, Inoue T, Tanaka IImprovement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci2002;71:227–38.
28.
28. Conarello SL, Li Z, Ronan J. et al.Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA2003;100:6825–30.
29.
29. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJDipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycaemic effects in anesthetized pigs. Diabetes2001;50:1588–97.
30.
30. Pederson RA, White HA, Schlenzig D, Pauly RP, Mcintosh CH, Demuth HUImproved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes1998;47:1253–8.
31.
31. Pospisilik JA, Stafford SG, Demuth HU. et al.Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinaemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes2002;51:943–50.
32.
32. Pospisilik JA, Martin J, Doty T. et al.Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in strepto-zotocin-induced diabetic rats. Diabetes2003;52:741–50.
33.
33. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li XInhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia1999;42:1324–31.
34.
34. Reimer MK, Holst JJ, Ahren BLong-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol2002;146:717–27.
35.
35. Mu J, Woods J, Zhou YP. et al.Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta cell mass and function in a rodent model of type 2 diabetes. Diabetes2006;55:1695–704.
36.
36. Burkey BF, Li X, Bolognese L. et al.Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther2005;315:688–95.
37.
37. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka IEnteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism2003;52:81–6.
38.
38. Mcintosh CH, Demuth HU, Kim SJ, Pospisilik JA, Pederson RAApplications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol2006;38:860–72.
39.
39. Hoffmann T, Lund K, Mcintosh CHDPP IV inhibition as treatment of type 2 diabetes. In: Cell-surface aminopeptidases: basic and clinical aspects. Mizupara S (Ed). New York: Elsevier, 2001, pp 381–7.
40.
40. Ahren B, Simonsson E, Larsson H. et al.Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care2002;25:869–75.
41.
41. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab2004;89:2078–84.
42.
42. Ristic S, Byiers S, Foley J, Holmes DImproved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab2005;7:692–8.
43.
43. Mari A, Sallas Wm, HE YL. et al.Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab2005;90:4888–94.
44.
44. D'alessio DA, Watson CE, HE Y-L. et al.Restoration of an acute insulin response to glucose in drug-naive patients with type 2 diabetes by 3-month treatment with vildagliptin. Diabetes2006;55:A454.
45.
45. Matikainen N, Manttari S, Schweizer A. et al.Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia2006;49:2049–57.
46.
46. Dejagers S, Lebeaut A, Couturier A, Schwizer ASustained reduction in HbA1 c during one-year treatment with vildagliptin in patients with type 2 diabetesDiabetes2006;55 (suppl 1):A120.
47.
47. Rosenstock J, Baron MA, Schweizer A, Mills D, Dejagers SVildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naïve patients with type 2 diabetes (T2DM). Diabetes2006;55(suppl 1):557–P.
48.
48. Ahren B, Gomis R, Standl E, Mills D, Schweizer ATwelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care2004;27:2874–80.
49.
49. Ahren B, Pacini G, Foley JE, Schweizer AImproved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care2005;28:1936–40.
50.
50. Stevens C, Van Dyck K, Yi B. et al.Single dose of MK-0431, an inhibitor of dipeptidyl peptidase-IV, raise active GLP-1 levels without causing hypoglycaemia in healthy subjects. Diabetes2005;54:493–P, abstract.
51.
51. Herman G, Hanefeld M, Wu M, Chen X, Zhao P, Stein PEffect of MK-0431, a dipeptidyl peptidase IV (DPP IV) inhibitor, on glycaemic control after 12 weeks in patients with type 2 diabetes. Diabetes2005;54:541-P, abstract.
52.
52. Raz I, Hanefeld M, Xu L. et al.Sitagliptin monotherapy improved glycaemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM). Diabetes2006;55 (suppl 1):1996-PO.
53.
53. Ascher P, Kipnes M, Lunceford J, Mickel C, Davies M, Williams-Herman D. Sitagliptin monotherapy improved glycaemic control in the fasting and postprandial states. Diabetes2006;55:A1995.
54.
54. Karasik A, Charbound B, Liu Ji, Wu M, Meehan A, Meininger G. Sitagliptin added to ongoing metformin therapy enhanced glycaemic control and beta-cell function. Diabetes2006;55:A501.
55.
55. Rosenstock J, Brazg R, Andryuk PJ, Sisk CM, Lu K, Stein PAddition of sitagliptin to pioglitazone improved glycaemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). Diabetes2006;55 (suppl 1):556-P.
56.
56. Brazg R, Thomas K, Zhao P, Xu L, Chen X, Stein PEffect of adding MK-0431 to ongoing metformin therapy in type 2 diabetic patients who have inadequate glycaemic control on metformin. Diabetes2005;54:11-OR, abstract.
57.
57. Vilsboll T, Krarup T, Sonne J. et al.Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab2003;88:2706–13.
58.
58. Dupre J, Behme MT, Hramiak IM, Mcdonald TJSubcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care1997;20:381–4.
59.
59. Jones B, Adams S, Miller GT, Jesson MI, Watanabe T, Wallner BPHematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood2003;102:1641–8.
60.
60. Lankas GR, Leiting B, Roy RS. et al.Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes2005;54:2988–94.
61.
61. Mannucci E, Ognibene A, Cremasco F. et al.Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care2001;24:489–94.
62.
62. Lenhard JM, Croom DK, Minnick DTReduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun2004;324:92–7.
63.
63. Lindsay JR, Duffy NA, Mckillop AM. et al.Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med2005;22:654–7.
64.
64. Green BD, Duffy NA, Irwin N, Gault VA, O'Harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV (DPP IV) activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (GLP-1). Eur J Pharmacol2006 (in press).
65.
65. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, Mcintosh CH, Demuth HU. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun2002;29:1302–08.
66.
66. Yasuda N, Inoue T, Nagakura T. et al.Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun2002;298:779–84.
67.
67. Mckillop AM, Duffy NA, Lindsay JR. et al.Insulinotropic actions of nateglinide are accompanied by inhibition of dipeptidyl peptidase-IV activity. Diabetologia2006;0796, abstract.
68.
68. Hupe-Sodmann K, Mcgregor GP, Bridenbaugh R. et al.Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept1995;58:149–56.
69.
69. Hupe-Sodmann K, Goke R, Goke B. et al.Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides1997;18:625–32.
70.
70. Plamboeck A, Holst JJ, Carr RD, Deacon CFNeutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia2005;48:1882–90.
